International Consensus Statement on the Clinical and Therapeutic Management of Leber Hereditary Optic Neuropathy.

Détails

ID Serval
serval:BIB_73E27A5BD142
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
International Consensus Statement on the Clinical and Therapeutic Management of Leber Hereditary Optic Neuropathy.
Périodique
Journal of neuro-ophthalmology
Auteur(s)
Carelli V., Carbonelli M., de Coo I.F., Kawasaki A., Klopstock T., Lagrèze W.A., La Morgia C., Newman N.J., Orssaud C., Pott JWR, Sadun A.A., van Everdingen J., Vignal-Clermont C., Votruba M., Yu-Wai-Man P., Barboni P.
ISSN
1536-5166 (Electronic)
ISSN-L
1070-8022
Statut éditorial
Publié
Date de publication
12/2017
Peer-reviewed
Oui
Volume
37
Numéro
4
Pages
371-381
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Résumé
Leber hereditary optic neuropathy (LHON) is currently estimated as the most frequent mitochondrial disease (1 in 27,000-45,000). Its molecular pathogenesis and natural history is now fairly well understood. LHON also is the first mitochondrial disease for which a treatment has been approved (idebenone-Raxone, Santhera Pharmaceuticals) by the European Medicine Agency, under exceptional circumstances because of the rarity and severity of the disease. However, what remains unclear includes the optimal target population, timing, dose, and frequency of administration of idebenone in LHON due to lack of accepted definitions, criteria, and general guidelines for the clinical management of LHON. To address these issues, a consensus conference with a panel of experts from Europe and North America was held in Milan, Italy, in 2016. The intent was to provide expert consensus statements for the clinical and therapeutic management of LHON based on the currently available evidence. We report the conclusions of this conference, providing the guidelines for clinical and therapeutic management of LHON.

Mots-clé
Antioxidants/therapeutic use, Congresses as Topic, Consensus, Disease Management, Humans, International Cooperation, Ophthalmology, Optic Atrophy, Hereditary, Leber/drug therapy, Societies, Medical, Ubiquinone/analogs & derivatives, Ubiquinone/therapeutic use
Pubmed
Web of science
Création de la notice
14/12/2017 19:56
Dernière modification de la notice
12/03/2018 18:58
Données d'usage